Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Study Overview

Detailed Description

Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.

Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.

Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.

This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H2X 3E4

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18 and 90 years old
  • ASA status I to III inclusively
  • Planned lower body surgery under spinal anesthesia with chloroprocaine
  • Signed informed consent form

Exclusion Criteria:

  • Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
  • Preexisting neuropathy or nerve block that could interfere with study assessments
  • Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
  • Preoperative use of corticosteroids
  • Patient refusal
  • Inability to consent
  • Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
  • Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
  • Perioperative intravenous dexmedetomidine administration
  • Conversion to general anesthesia
  • Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
  • Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intravenous dexamethasone

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine

Other Names:
  • Decadron
Placebo Comparator: Intravenous normal saline

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine

Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Regression of sensory block by 2 dermatomes
Time Frame: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level

At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of motor block
Time Frame: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Time until the first observable regression of the motor block
Time Frame: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale.

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Onset of sensory block
Time Frame: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation

Up to 30 minutes following spinal anesthesia
Onset of motor block
Time Frame: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale

Up to 30 minutes following spinal anesthesia
Quality of motor block
Time Frame: Up to 30 minutes following spinal anesthesia

Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block.

The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block.

Up to 30 minutes following spinal anesthesia
Opioid consumption
Time Frame: At recovery room discharge, approximately one hour after the end of surgery

Total dose of opioids

At recovery room discharge, approximately one hour after the end of surgery
Antiemetic consumption
Time Frame: At recovery room discharge, approximately one hour after the end of surgery

Total dose of antiemetics

At recovery room discharge, approximately one hour after the end of surgery
Incidence of hypotension
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Systolic blood pressure lower than 90 mm Hg

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of bradycardia
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Heart rate slower than 50 beats per minute

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of nausea
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of nausea reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of vomiting
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of retching or vomiting reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of itching
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of itching reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of urinary retention
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of urinary retention reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of shivering
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of shivering reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of headache
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of headache reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Quality of postoperative recovery
Time Frame: At 24 hours after the surgery

QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome).

At 24 hours after the surgery
Intensity of nausea/vomiting
Time Frame: At 24 hours after surgery

Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Pain intensity
Time Frame: At 24 hours after surgery

Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Quality of sleep
Time Frame: At 24 hours after surgery

Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Surgeon's satisfaction towards spinal anesthesia
Time Frame: At the end of surgery, on the day of randomization

Unsatisfied or satisfied

At the end of surgery, on the day of randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stephan Williams, MD, PhD, Santé Québec - CHUM

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

September 18, 2026

First Submitted That Met QC Criteria

September 18, 2026

First Posted (Actual)

September 23, 2026

Study Record Updates

Last Update Posted (Actual)

October 8, 2026

Last Update Submitted That Met QC Criteria

October 5, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe